Non-severe SARS-CoV-2 infection is characterised by very early T cell proliferation independent of type 1 interferon responses and distinct from other acute respiratory viruses
Data Availability
Open access to RNAseq and TCRseq data and associated essential metadata will be made available after peer-reviewed publication. Applications for access to the individual participant de-identified data (including data dictionaries) and samples can be made to the access committee via an online application https://covid-consortium.com/application-for-samples/. Each application will be reviewed, with decisions to approve or reject an application for access made on the basis of (i) accordance with participant consent and alignment to the study objectives (ii) evidence for the capability of the applicant to undertake the specified research and (iii) availability of the requested samples. The use of all samples and data will be limited to the approved application for access and stipulated in the material and data transfer agreements between participating sites and investigators requesting access.
Subject Area
- Addiction Medicine (390)
- Allergy and Immunology (705)
- Anesthesia (196)
- Cardiovascular Medicine (2877)
- Dermatology (245)
- Emergency Medicine (432)
- Epidemiology (12604)
- Forensic Medicine (10)
- Gastroenterology (811)
- Genetic and Genomic Medicine (4476)
- Geriatric Medicine (407)
- Health Economics (717)
- Health Informatics (2867)
- Health Policy (1057)
- Hematology (378)
- HIV/AIDS (907)
- Medical Education (418)
- Medical Ethics (115)
- Nephrology (465)
- Neurology (4233)
- Nursing (226)
- Nutrition (619)
- Oncology (2218)
- Ophthalmology (631)
- Orthopedics (255)
- Otolaryngology (322)
- Pain Medicine (270)
- Palliative Medicine (83)
- Pathology (489)
- Pediatrics (1182)
- Primary Care Research (485)
- Public and Global Health (6818)
- Radiology and Imaging (1502)
- Respiratory Medicine (907)
- Rheumatology (430)
- Sports Medicine (373)
- Surgery (475)
- Toxicology (59)
- Transplantation (204)
- Urology (175)